Lotte Bio-APTIS, Joint Development Agreement for Next-Generation ADC Toolbox

[Financial News] Lotte Biologics announced on the 11th that it has signed a Memorandum of Understanding (MOU) for cooperation on the next-generation ADC toolbox with APTIS, a company developing antibody-drug conjugates (ADC) of the Dong-A Socio Group. Through this agreement, the two companies plan to link APTIS's AbClick technology with Lotte Biologics' conjugation production services at the Syracuse facility and promote joint marketing.
In addition, they plan to strengthen competitiveness in the ADC-related new drug development and contract development and manufacturing organization (CDMO) market for domestic and international pharmaceutical and biotech companies by expanding the scope of Lotte Biologics' ADC toolbox.
In the future, the two companies will also conduct a preliminary feasibility study on AbClick technology at the Syracuse production facility to build the ADC toolbox.
Currently, Lotte Biologics provides ADC toolbox services that allow customers to select and utilize various technologies according to their needs, along with its proprietary SoluFlex Link technology. Furthermore, the company is engaged in order-taking activities by providing one-stop service solutions for ADC development, manufacturing, clinical, and commercial antibody production.
APTIS possesses the third-generation linker technology AbClick platform. AbClick can selectively bind drugs to specific sites on the antibody Fc domain, eliminating the need for mutant antibody production, which is a strength. It ensures a uniform antibody-drug ratio (DAR), guaranteeing high quality as a differentiated advantage.
Park Je-Ims, CEO of Lotte Biologics, said, "This agreement will be an opportunity to maximize the technological competitiveness of both companies," adding, "We will strive to become a company that contributes to improving the quality of life for patients, as well as developing differentiated ADC therapeutics."
Han Tae-Dong, CEO of APTIS, said, "I have high expectations for the agreement with Lotte Biologics, which has entered the ADC field based on its long-standing know-how in antibody production," adding, "I hope that the combination of the two companies' technologies will secure competitiveness on the global stage."

vrdw88@fnnews.com Kang Jung-Mo Reporter